New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
07:13 EDTCOVCorrection: Covidien shares should be bought on pullbacks, says RBC Capital
After Covidien reported better than expected Q1 results and the company reiterated its previous FY14 revenue guidance but slightly raised its tax rate guidance, RBC Capital has increased confidence in the company's operating margin outlook. The firm thinks the company looks well-positioned to return to double-digit EPS growth in F2H14. However, it keeps a Sector Perform rating on the shares. A previous article incorrectly stated that the firm had an Outperform rating on the stock.
News For COV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 4, 2014
11:23 EDTCOVAppeals court reverses patent ruling in favor of J&J unit over Covidien
Ethicon Endo-Surgery, a Johnson & Johnson (JNJ) company, appealed a district court judgment regarding certain asserted patent claims of Tyco Healthcare. The appeals court affirmed-in-part, reversed-in-part, and vacated-in-part the prior judgment, because the lower courtís 102(g) findings were correct, but its 103 determination was improper, "including its decision to exclude the 102(g) prior art from the obviousness analysis," the court stated. In 2007, Tyco Healthcare changed its name to Covidien (COV). Reference Link
08:24 EDTCOVChinese Ministry of Commerce clears Medtronic acquisition of Covidien
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use